GRIP-1 Inhibitors
The chemical class known as GRIP-1 Inhibitors comprises a diverse array of compounds that either directly or indirectly modulate the activity of GRIP-1, a pivotal protein in various cellular processes. Among these inhibitors, Griffipavixanthone stands out as a direct antagonist, exerting its inhibitory effect by specifically binding to the active site of GRIP-1. This interaction impedes the protein's ability to interact with its substrates, thereby disrupting its integral role in cellular processes. Importantly, the specificity of Griffipavixanthone ensures a targeted approach, selectively impacting GRIP-1 without affecting other proteins. Additionally, a group of indirect inhibitors, including AMG-232, JQ1, SB-431542, NSC 23766, LY-2157299, SB-202190, Nilotinib, PD173955, LY2874455, PI-103, and BAY 11-7082, has been identified. These compounds exert their inhibitory effects by targeting signaling pathways interconnected with GRIP-1. For instance, AMG-232 disrupts the MDM2-p53 interaction, influencing pathways involving both p53 and GRIP-1. Each compound within this class modulates key elements within these pathways, thereby affecting downstream events that may intersect with GRIP-1-mediated cellular processes. This indirect inhibition approach provides a nuanced means to regulate GRIP-1 activity by intervening at various points within its regulatory network.
The diversity in mechanisms exhibited by GRIP-1 Inhibitors underscores the intricate nature of cellular signaling networks and for targeted pharmacological interventions. These inhibitors serve as valuable tools for scientific inquiry, offering researchers the ability to dissect and understand the nuanced roles of GRIP-1 in cellular functions. Overall, the detailed exploration of these inhibitors provides a foundation for advancing our understanding of cellular processes governed by GRIP-1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a BET bromodomain inhibitor, indirectly modulates GRIP-1 activity by affecting the expression of genes involved in related pathways. Through inhibition of BET bromodomains, JQ1 alters chromatin structure and gene transcription, influencing cellular processes downstream of GRIP-1. This indirect inhibition provides a means to regulate GRIP-1 activity by targeting its transcriptional regulatory network. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 serves as an indirect inhibitor of GRIP-1 by targeting the TGF-β signaling pathway. By inhibiting the TGF-β type I receptor, SB-431542 disrupts downstream signaling events that may intersect with GRIP-1 pathways. This indirect inhibition affects cellular responses governed by both TGF-β and GRIP-1, providing a regulatory mechanism through the modulation of shared signaling pathways. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY-2157299 serves as an indirect inhibitor of GRIP-1 by targeting the TGF-β type I receptor kinase. By inhibiting this kinase, LY-2157299 disrupts TGF-β signaling, which may intersect with pathways involving GRIP-1. This indirect inhibition affects cellular responses governed by both TGF-β and GRIP-1, providing a regulatory mechanism through the modulation of shared signaling pathways. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB-202190 acts as an indirect inhibitor of GRIP-1 by specifically inhibiting p38 MAPK, a kinase involved in cellular processes regulated by GRIP-1. Through p38 MAPK inhibition, SB-202190 disrupts downstream pathways governed by GRIP-1, influencing cellular functions such as gene expression and cytokine production. This indirect inhibition provides a targeted approach to modulate GRIP-1-related processes by focusing on specific components of its regulatory network. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib serves as an indirect inhibitor of GRIP-1 by targeting the ABL kinases. Through inhibition of ABL kinases, Nilotinib influences downstream signaling events that may intersect with GRIP-1 pathways. This indirect inhibition affects cellular responses governed by both ABL kinases and GRIP-1, providing a regulatory mechanism through the modulation of shared signaling pathways. | ||||||
PD 173955 | 260415-63-2 | sc-507378 | 10 mg | $320.00 | ||
PD173955 acts as an indirect inhibitor of GRIP-1 by targeting the EGFR signaling pathway. By inhibiting EGFR tyrosine kinase activity, PD173955 disrupts downstream signaling events that may intersect with GRIP-1 pathways. This indirect inhibition affects cellular responses governed by both EGFR and GRIP-1, providing a regulatory mechanism through the modulation of shared signaling pathways. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 serves as an indirect inhibitor of GRIP-1 by targeting the PI3K/AKT/mTOR signaling pathway. By inhibiting PI3K, PI-103 disrupts downstream signaling events that may intersect with GRIP-1 pathways. This indirect inhibition affects cellular responses governed by both PI3K and GRIP-1, providing a regulatory mechanism through the modulation of shared signaling pathways. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 serves as an indirect inhibitor of GRIP-1 by specifically inhibiting the NF-κB pathway. Through NF-κB inhibition, BAY 11-7082 disrupts downstream signaling events that may intersect with GRIP-1 pathways. This indirect inhibition affects cellular responses governed by both NF-κB and GRIP-1, providing a regulatory mechanism through the modulation of shared signaling pathways. | ||||||